{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:49Z","timestamp":1789506709283,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128938","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:26:56Z","timestamp":1784723216000},"page":"128938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["mRNA-LNP hepatitis C vaccine encoding p7 elicits improved humoral immunogenicity"],"prefix":"10.1016","volume":"88","author":[{"given":"Erin K.","family":"Reagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara","family":"Mercado-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Atochina-Vasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houping","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Mui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine J.","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128938_bb0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.athoracsur.2020.04.003","article-title":"Adult cardiac surgery during the COVID-19 pandemic: a tiered patient triage guidance statement","volume":"110","author":"Haft","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.vaccine.2026.128938_bb0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128938_bb0015","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2026.128938_bb0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, Progress, and challenges to hepatitis C vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0025","series-title":"Global hepatitis report 2024","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128938_bb0030","series-title":"Projected U.S. national Hepatitis C treatment costs and estimated reduction to medical costs","author":"Cline","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128938_bb0035","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14712598.2013.791277","article-title":"Ever closer to a prophylactic vaccine for HCV","volume":"13","author":"Swadling","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2026.128938_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz415.2493","article-title":"A randomized, double-blind, placebo-controlled efficacy trial of a vaccine to prevent chronic hepatitis C virus infection in an at-risk population","volume":"6","author":"Cox","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128938_bb0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128938_bb0050","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a036962","article-title":"Antibody responses in hepatitis c infection","volume":"11","author":"Law","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2026.128938_bb0060","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1128\/JVI.01194-15","article-title":"Immunoglobulin with high-titer in vitro cross-neutralizing hepatitis C virus antibodies passively protects chimpanzees from homologous, but not heterologous, challenge","volume":"89","author":"Bukh","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0065","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128938_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.02163","article-title":"The rationale for a preventative HCV virus-like particle (VLP) vaccine","volume":"8","author":"Torresi","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/erv.13.10","article-title":"Virus-like particle-based vaccines against hepatitis C virus infection","volume":"12","author":"Bellier","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128938_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2026.128938_bb0090","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/j.vaccine.2007.08.053","article-title":"Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies","volume":"25","author":"Stamataki","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128938_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","article-title":"T cell responses in hepatitis C virus infection: historical overview and goals for future research","author":"Holz","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2026.128938_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001087","article-title":"Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production","volume":"6","author":"Wozniak","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128938_bb0105","doi-asserted-by":"crossref","first-page":"0962","DOI":"10.1371\/journal.ppat.0030103","article-title":"Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions","volume":"3","author":"Steinmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128938_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003355","article-title":"Hepatitis C virus p7 is critical for capsid assembly and envelopment","volume":"9","author":"Gentzsch","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128938_bb0115","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0016-5085(99)70290-8","article-title":"Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate","volume":"117","author":"Baumert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0120","first-page":"221","article-title":"In vitro transcription of long RNA containing modified nucleosides","volume":"969","author":"Pardi","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.vaccine.2026.128938_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00976-z","article-title":"Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection","volume":"9","author":"Atochina-Vasserman","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128938_bb0135","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00048-17","article-title":"Identification of novel functions for hepatitis C virus envelope glycoprotein E1 in virus entry and assembly","volume":"91","author":"Haddad","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0140","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-018-0449-x","article-title":"Nucleocapsid protein-dependent assembly of the RNA packaging signal of Middle East respiratory syndrome coronavirus","volume":"25","author":"Hsin","year":"2018","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.vaccine.2026.128938_bb0150","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.vaccine.2019.05.066","article-title":"Purification of flavivirus VLPs by a two-step chomatographic process","volume":"37","author":"Lima","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128938_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21769\/BioProtoc.3280","article-title":"Production and purification of dengue virus-like particles from COS-1 cells","volume":"9","author":"Galula","year":"2019","journal-title":"Bio-Protocol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0160","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001512","article-title":"Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins","volume":"102","author":"Kalemera","year":"2021","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0165","doi-asserted-by":"crossref","unstructured":"Mimms, J. L. et al. Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent. J Gen Virol 107, 1\u201310 (2026).","DOI":"10.1099\/jgv.0.002201"},{"key":"10.1016\/j.vaccine.2026.128938_bb0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128938_bb0175","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles","volume":"76","author":"Clayton","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0180","first-page":"742","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"57","author":"Pardi","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2026.128938_bb0185","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2026.128938_bb0190","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1086\/315450","article-title":"Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C","volume":"181","author":"Gr\u00fcner","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128938_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21165644","article-title":"Adaptive immune response against hepatitis c virus","volume":"21","author":"Kemming","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128938_bb0200","article-title":"An antigenically diverse, representative panel of envelope glycoproteins for HCV vaccine development","author":"Salas","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0205","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128938_bb0210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","article-title":"Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice","volume":"34","author":"Lechmann","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2026.128938_bb0215","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1128\/JVI.72.5.3827-3836.1998","article-title":"Hepatitis C virus structural proteins assemble into viruslike particles in insect cells","volume":"72","author":"Baumert","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0220","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/JVI.76.8.4073-4079.2002","article-title":"Hepatitis C virus-like particle morphogenesis","volume":"76","author":"Blanchard","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128938_bb0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.virusres.2013.06.008","article-title":"Evidence suggesting that HCV p7 protects E2 glycoprotein from premature degradation during virus production","volume":"176","author":"Atoom","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.128938_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059776","article-title":"A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans","volume":"8","author":"Law","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128938_bb0235","doi-asserted-by":"crossref","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"Tam","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128938_bb0240","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128938_bb0245","first-page":"12","article-title":"Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity","volume":"42","author":"Patra","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128938_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140590","article-title":"Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion","volume":"131","author":"Salinas","year":"2021","journal-title":"J Clin Invest"},{"issue":"378","key":"10.1016\/j.vaccine.2026.128938_bb0255","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"80","author":"Arevalo","year":"2022","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:42:34Z","timestamp":1789504954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S0264410X26007474"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128938","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA-LNP hepatitis C vaccine encoding p7 elicits improved humoral immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128938"}}